BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  HedgePath Pharma Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update

  HedgePath Pharma announced today that it has completed enrollment in its previously announced open label, Phase 2b SCORING clinical trial, testing SUBA-Itraconazole in patients with BCCNS.

  October 30, 2017

   · 

  9 min read
• Pharm Country

  Equashield and Palex Medical Expand CSTD Distribution to Portuguese Market

  Following Equashield’s successful entry into the Spanish market with Palex Medical SA, the company will expand its current relationship with the distributor to bring its CSTD to Portugal

  October 30, 2017

   · 

  4 min read
• Policy

  Bayer Announces BAY94-9027 BLA Accepted by FDA

  The FDA has accepted Bayer’s BLA filing for BAY94-902 for the treatment of hemophilia A in adults and adolescents 12 years of age and over.

  October 30, 2017

   · 

  4 min read
• Business

  Pulmatrix Appoints Dr. James Roach as Chief Medical Officer

  Pulmatrix today announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new CMO, effective November 3, 2017.

  October 30, 2017

   · 

  5 min read
• Drug Development

  Can-Fite Announces Enrollment of First Patient in Its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis

  This randomized, double-blind, active and placebo-controlled study will enroll approximately 500 patients through clinical sites in Europe, Israel and Canada.

  October 30, 2017

   · 

  6 min read
• Business

  CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

  The novel production facility - called GMP IV - will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expected to be fully commissioned in 2019.

  October 30, 2017

   · 

  2 min read
• Business

  Cerveau Technologies Announces a Partnership With Landmark Alzheimer’s Disease DIAN-TU Trial

  The trial will include Cerveau’s MK-6240, an investigational imaging biomarker targeting disease progression.

  October 30, 2017

   · 

  3 min read
• Policy

  Marrone Bio Innovations Receives EPA Approval for Novel Biofungicide

  Stargus is proven highly effective for controlling downy mildews and white molds.

  October 30, 2017

   · 

  5 min read
• Business

  Marrone Bio Innovations to Report Third Quarter 2017 Financial Results and Host a Conference Call on Monday, November 13th at 1:30 p.m. Pacific Time

  Management will host an investor conference call the same day to discuss the results, provide a corporate update, and conclude with a Q&A from participants.

  October 30, 2017

   · 

  3 min read
• Biotech Bay

  Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months

  The company has Initiated Pivotal Trial for the MobiusHD in the US and EU

  October 30, 2017

   · 

  4 min read